Table 5.
Statistical methods for analysis of new infections in therapeutic efficacy studies from sub-Saharan Africa
| Exclude | Treat as ACPR | Unclear | ||||||
|---|---|---|---|---|---|---|---|---|
| N | n | % | n | % | n | % | P-value* | |
| Study region | ||||||||
| West Africa | 73 | 11 | 15 | 44 | 60 | 18 | 25 | 0.0003 |
| Central Africa | 32 | 16 | 50 | 14 | 44 | 2 | 6 | |
| East Africa | 53 | 19 | 36 | 31 | 58 | 3 | 6 | |
| Southern Africa | 17 | 7 | 41 | 10 | 59 | 0 | 0 | |
| Study explicitly describes statistical methods | ||||||||
| Yes | 38 | 20 | 53 | 17 | 45 | 1 | 3 | 0.0002 |
| No | 159 | 33 | 21 | 101 | 64 | 25 | 16 | |
| Study presents the Kaplan–Meier estimate | ||||||||
| Yes | 57 | 34 | 60 | 20 | 35 | 3 | 5 | < 0.0001 |
| No | 140 | 19 | 14 | 98 | 70 | 23 | 16 | |
| Study cites the WHO protocol | ||||||||
| Yes | 172 | 53 | 31 | 97 | 56 | 22 | 13 | 0.0049 |
| No | 25 | 0 | 0 | 21 | 84 | 4 | 16 | |
ACPR = adequate clinical and parasitological response; N = number of articles assessed; n = number of articles with a finding.
*
Difference between rates of studies excluding or reclassifying as ACPR, calculated using chi-squared test.